We are live on ! Find out more
CRSP icon

CRISPR Therapeutics

417 hedge funds and large institutions have $3.07B invested in CRISPR Therapeutics in 2023 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 94 increasing their positions, 137 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

141% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 27

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

27% more call options, than puts

Call options by funds: $142M | Put options by funds: $112M

9% more funds holding

Funds holding: 382 → 417 (+35)

2.09% less ownership

Funds ownership: 71.49% → 69.41% (-2.1%)

31% less repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 137

32% less capital inflows, than outflows

Capital inflows: $171M | Capital outflows: $250M

Holders
417
Holders Change
+35
Holders Change %
+9.16%
% of All Funds
6.52%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
65
Increased
94
Reduced
137
Closed
27
Calls
$142​M
Puts
$112​M
Net Calls
+$30​M
Net Calls Change
+$22.1​M

CRSP Hedge Fund Activity: Q2 2023 in Review

417 of the 6,391 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2023, worth a combined $3.07B — up 21% from $2.54B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new CRSP positions and 27 closed out — a net gain of 38 holders — while 94 added to existing stakes and 137 trimmed.

The largest buyer was Marshall Wace, opening a new position worth an estimated $25.9M. The largest seller was ARK Investment Management, cutting an estimated $37M.

  • 417 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2023, up from 382 in Q1 2023.
  • Funds reported $3.07B of CRISPR Therapeutics stock for Q2 2023, up 21% quarter-over-quarter.
  • 65 funds opened new CRISPR Therapeutics positions in Q2 2023 and 27 closed out, a net change of +38 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2023 was Marshall Wace, an estimated $25.9M added.
  • The largest CRISPR Therapeutics seller in Q2 2023 was ARK Investment Management, an estimated $37M sold.

Based on aggregated 13F filings for Q2 2023.